

# Identification of multiple cancer-associated myositis-specific inflammatory myopathies: a large longitudinal cohort study

Arthritis Research and Therapy

19, 259

DOI: [10.1186/s13075-017-1469-8](https://doi.org/10.1186/s13075-017-1469-8)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Autoantibodies in myositis. <i>Nature Reviews Rheumatology</i> , 2018, 14, 290-302.	3.5	248
2	The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy. <i>Clinical Rheumatology</i> , 2018, 37, 1573-1580.	1.0	10
3	Dermatomyositis as a paraneoplastic phenomenon in oesophageal cancer. <i>BMJ Case Reports</i> , 2018, 11, e227387.	0.2	1
4	Clinical significance of myositis-specific autoantibodies. <i>Immunological Medicine</i> , 2018, 41, 103-112.	1.4	34
5	Proximal muscle weakness and skin rash. <i>BMJ: British Medical Journal</i> , 2018, 363, k3614.	2.4	0
6	New insights in myositis-specific autoantibodies. <i>Current Opinion in Rheumatology</i> , 2018, 30, 614-622.	2.0	37
7	The diagnostic work-up of cancer-associated myositis. <i>Current Opinion in Rheumatology</i> , 2018, 30, 630-636.	2.0	37
8	The clinical application of tumor markers in the screening of malignancies and interstitial lung disease of dermatomyositis/polymyositis patients: A retrospective study. <i>SAGE Open Medicine</i> , 2018, 6, 205031211878189.	0.7	14
10	Polymyositis and dermatomyositis – challenges in diagnosis and management. <i>Journal of Translational Autoimmunity</i> , 2019, 2, 100018.	2.0	44
11	Risk of Cancers in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from the Korea National Health Insurance Claims Database 2010–2018. <i>Journal of Clinical Medicine</i> , 2019, 8, 1871.	1.0	10
12	Frequencies and clinical associations of myositis-related antibodies in The Netherlands: A one-year survey of all Dutch patients. <i>Journal of Translational Autoimmunity</i> , 2019, 2, 100013.	2.0	34
13	Lung Diseases in Inflammatory Myopathies. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2019, 40, 255-270.	0.8	30
14	Anti-OJ autoantibodies: Rare or underdetected?. <i>Autoimmunity Reviews</i> , 2019, 18, 658-664.	2.5	48
15	Autoantibody testing in idiopathic inflammatory myopathies. <i>Practical Neurology</i> , 2019, 19, 284-294.	0.5	16
16	Lung adenocarcinoma and anti-transcriptional intermediary factor 1γ positive dermatomyositis complicated with spontaneous oesophageal rupture. <i>Respirology Case Reports</i> , 2019, 7, e00403.	0.3	4
17	Dermatomyositis antibodies continue to myositis-specific TIF-γ. <i>British Journal of Dermatology</i> , 2019, 180, 709-710.	1.4	1
18	Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy. <i>Rheumatology</i> , 2019, 58, 1655-1661.	0.9	20
19	Biomarkers in Adult Dermatomyositis: Tools to Help the Diagnosis and Predict the Clinical Outcome. <i>Journal of Immunology Research</i> , 2019, 2019, 1-15.	0.9	18

#	ARTICLE	IF	CITATIONS
20	18F-FDG PET/CT versus conventional investigations for cancer screening in autoimmune inflammatory myopathy in the era of novel myopathy classifications. <i>Nuclear Medicine Communications</i> , 2019, 40, 377-382.	0.5	27
21	Cancer and Idiopathic Inflammatory Myositis. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 231-241.	0.6	2
22	The role of cancer-associated autoantibodies as biomarkers in paraneoplastic myositis syndrome. <i>Current Opinion in Rheumatology</i> , 2019, 31, 643-649.	2.0	32
23	Association of anti-nuclear matrix protein 2 antibody with complications in patients with idiopathic inflammatory myopathies: A meta-analysis of 20 cohorts. <i>Clinical Immunology</i> , 2019, 198, 11-18.	1.4	20
24	Autoantibodies in idiopathic inflammatory myopathies: Clinical associations and laboratory evaluation by mono- and multispecific immunoassays. <i>Autoimmunity Reviews</i> , 2019, 18, 293-305.	2.5	100
25	Nivolumab-induced anti-aminoacyl-tRNA synthetase antibody-positive polymyositis complicated by interstitial pneumonia in a patient with lung adenocarcinoma. <i>Scandinavian Journal of Rheumatology</i> , 2020, 49, 82-83.	0.6	7
26	Dermatomyositis: Diagnosis and treatment. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 283-296.	0.6	75
27	239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. <i>Neuromuscular Disorders</i> , 2020, 30, 70-92.	0.3	148
28	Increased risk of malignancy in patients aged over 50 with idiopathic inflammatory myositis compared to patients with osteoarthritis of the knee. <i>Modern Rheumatology</i> , 2020, 30, 870-877.	0.9	1
29	Retrospective Analysis of Cancer-Associated Myositis Patients over the Past 3 Decades in a Hungarian Myositis Cohort. <i>Pathology and Oncology Research</i> , 2020, 26, 1749-1755.	0.9	30
30	Anti-TIF1- $\beta$ autoantibodies: warning lights of a tumour autoantigen. <i>Rheumatology</i> , 2020, 59, 469-477.	0.9	43
31	A high level of serum neopterin is associated with rapidly progressive interstitial lung disease and reduced survival in dermatomyositis. <i>Clinical and Experimental Immunology</i> , 2020, 199, 314-325.	1.1	27
32	Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 79-89.	1.3	14
33	A novel autoantibody targeting calreticulin is associated with cancer in patients with idiopathic inflammatory myopathies. <i>Clinical and Translational Immunology</i> , 2020, 9, e1195.	1.7	5
34	Immune-mediated necrotizing myopathy: clinical features and pathogenesis. <i>Nature Reviews Rheumatology</i> , 2020, 16, 689-701.	3.5	131
35	Comment on "Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy". <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e459-e460.	0.6	3
36	Response to: Comment on "Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy". <i>Journal of the American Academy of Dermatology</i> , 2020, 83, e461-e462.	0.6	1
37	Where are we moving in the classification of idiopathic inflammatory myopathies?. <i>Current Opinion in Neurology</i> , 2020, 33, 590-603.	1.8	68

#	ARTICLE	IF	CITATIONS
39	Clinical characteristics and prognostic analysis of Chinese dermatomyositis patients with malignancies. <i>Medicine (United States)</i> , 2020, 99, e21899.	0.4	5
40	Characteristics of hospitalized dermatomyositis patients with underlying malignancy: a nationally representative retrospective cohort study. <i>Archives of Dermatological Research</i> , 2021, 313, 473-482.	1.1	4
41	Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3054.	1.8	41
42	Temporal relationship between idiopathic inflammatory myopathies and malignancies and its mortality: a nationwide population-based study. <i>Clinical Rheumatology</i> , 2020, 39, 3409-3416.	1.0	5
43	Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies. <i>Clinical Rheumatology</i> , 2020, 39, 3489-3497.	1.0	21
44	Anti-Mi-2 antibodies characterize a distinct clinical subset of dermatomyositis with favourable prognosis. <i>European Journal of Dermatology</i> , 2020, 30, 151-158.	0.3	24
45	Risk Factors and Cancer Screening in Myositis. <i>Rheumatic Disease Clinics of North America</i> , 2020, 46, 565-576.	0.8	28
46	Value of 18F-FDG PET/CT in the detection of occult malignancy in patients with dermatomyositis. <i>Heliyon</i> , 2020, 6, e03707.	1.4	18
47	The relationships between cancer and autoimmune rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101472.	1.4	30
48	Analysis of myositis autoantibodies in Chinese patients with cancer-associated myositis. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23307.	0.9	7
49	Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies. <i>Acta Neurologica Scandinavica</i> , 2021, 143, 131-139.	1.0	14
50	Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. <i>Clinical Rheumatology</i> , 2021, 40, 819-832.	1.0	16
51	The association between myositis-specific autoantibodies and muscle pathologies in idiopathic inflammatory myopathies. <i>Clinical Rheumatology</i> , 2021, 40, 613-624.	1.0	6
52	Myositis Antibodies and Interstitial Lung Disease. <i>Journal of Applied Laboratory Medicine</i> , 2022, 7, 240-258.	0.6	11
53	Paraneoplastic neurological syndrome: an evolving story. <i>Neuro-Oncology Practice</i> , 2021, 8, 362-374.	1.0	5
54	Overall and site-specific cancer before and after diagnosis of idiopathic inflammatory myopathies: A nationwide study 2002-2016. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 331-337.	1.6	19
55	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021, 60, 2615-2628.	0.9	69
56	Real world utilization of the myositis autoantibody panel. <i>Clinical Rheumatology</i> , 2021, 40, 3195-3205.	1.0	7

#	ARTICLE	IF	CITATIONS
57	Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody. <i>Clinical Rheumatology</i> , 2021, 40, 3695-3702.	1.0	11
58	Dermatomyositis autoantibodies: how can we maximize utility?. <i>Annals of Translational Medicine</i> , 2021, 9, 433-433.	0.7	20
59	Detection of multiple myositis-specific autoantibodies in unique patients with idiopathic inflammatory myopathy: A single centre-experience and literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 486-494.	1.6	8
60	Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review. <i>Frontiers in Immunology</i> , 2021, 12, 672008.	2.2	8
61	Long-term Follow-up and Muscle Imaging Findings in Brachio-Cervical Inflammatory Myopathy. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	3.1	4
62	Alloimmune Myositis as Paraneoplastic Complication of an Oral Squamous Cell Carcinoma After Severe Chronic Graft vs Host Disease or a Manifestation of Chronic Graft vs Host Disease? A Case Report and Literature Discussion. <i>Transplantation Proceedings</i> , 2021, 53, 1365-1368.	0.3	0
63	A Case Report of Anorectal Squamous Cell Carcinoma Associated with Overlap Myositis Syndromeâ€”a Possible Paraneoplastic Myositis Syndrome. <i>Clinical Colorectal Cancer</i> , 2021, 20, 148-152.	1.0	1
64	Severe onset of inflammatory myositis in a child: think to paraneoplastic myositis. <i>Italian Journal of Pediatrics</i> , 2021, 47, 146.	1.0	0
65	Recognition and Management of Cutaneous Connective Tissue Diseases. <i>Medical Clinics of North America</i> , 2021, 105, 757-782.	1.1	3
66	Polymyositis That Developed During Osimertinib Administration for Lung Adenocarcinoma. <i>Japanese Journal of Lung Cancer</i> , 2021, 61, 322-326.	0.0	0
67	Myositis autoantibodies in Iranian myositis patients: assessment the frequency and clinical relevancy. <i>Clinical Rheumatology</i> , 2021, , 1.	1.0	1
68	Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 872-878.	0.5	36
69	Malignancy in a retrospective cohort of 17 patients with Dermatomyositis or Polymyositis in southern Tunisia. <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , 2018, 56, 243-249.	0.3	5
70	Autoantibodies in Myositis. How to Achieve a Comprehensive Strategy for Serological Testing. <i>Mediterranean Journal of Rheumatology</i> , 2019, 30, 155.	0.3	5
71	Efficacy and Safety of Rituximab in Korean Patients with Refractory Inflammatory Myopathies. <i>Journal of Korean Medical Science</i> , 2020, 35, e335.	1.1	4
72	Rapidly Progressive Multiple Digital Gangrene and Diffuse Alveolar Damage in a Patient With Antisynthetase Antibody and Gastric Cancer. <i>Journal of Clinical Rheumatology</i> , 2018, Publish Ahead of Print, .	0.5	1
73	Myopathien. , 2019, , 521-529.		0
74	A Case of Small Cell Lung Cancer with Anti-Transcription Intermediary Factor 1 (TIF1)-Î³ Antibody-positive Dermatomyositis as Paraneoplastic Syndrome. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 158-162.	0.0	2

#	ARTICLE	IF	CITATIONS
75	Pulmonary involvement in inflammatory myopathies. , 2019, , 68-89.		1
76	Risk factors for cancer-associated myositis: A large-scale multicenter cohort study. International Journal of Rheumatic Diseases, 2021, 24, 268-273.	0.9	11
77	Dermatomyositis como síndrome paraneoplásico. Revista Medica Sinergia, 2020, 5, e534.	0.0	1
78	Triggers of inflammatory myopathy: insights into pathogenesis. Discovery Medicine, 2018, 25, 75-83.	0.5	22
79	Exploring Road of Classification Criteria for Idiopathic Inflammatory Myopathy. Chinese Medical Journal, 2018, 131, 2773-2775.	0.9	0
80	Update on Myositis Therapy: from Today's Standards to Tomorrow's Possibilities. Current Pharmaceutical Design, 2021, 27, .	0.9	2
81	Update on Malignancy in Myositis—Well-Established Association with Unmet Needs. Biomolecules, 2022, 12, 111.	1.8	10
82	An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. Clinical Reviews in Allergy and Immunology, 2022, 63, 240-250.	2.9	6
83	Using autoantibody signatures to define cancer risk in dermatomyositis. Journal of Clinical Investigation, 2022, 132, .	3.9	4
84	Cancer screening in idiopathic inflammatory myopathies: Ten years experience from a single center. Seminars in Arthritis and Rheumatism, 2022, 53, 151940.	1.6	5
85	Neurological complications of lung cancer. , 2022, , 243-276.		0
86	Anti-nuclear Matrix Protein 2 Antibody-positive Dermatomyositis Associated with Cervical Cancer Recurrence after 6 Years of Stable Disease. Internal Medicine, 2022, 61, 3445-3448.	0.3	3
87	Machine Learning Algorithms Identify Clinical Subtypes and Cancer in Anti-TIF1 <sup>+</sup> Myositis: A Longitudinal Study of 87 Patients. Frontiers in Immunology, 2022, 13, 802499.	2.2	4
88	Gastrointestinal Perforation in a Patient With Antinuclear Matrix Protein 2 Antibody-Positive Dermatomyositis. Arthritis Care and Research, 2022, 74, 1409-1415.	1.5	1
89	Antibody Therapies in Autoimmune Inflammatory Myopathies: Promising Treatment Options. Neurotherapeutics, 2022, 19, 911-921.	2.1	7
90	Myositis-specific antibodies: Overview and clinical utilization. Rheumatology and Immunology Research, 2022, 3, 1-10.	0.2	11
91	Clinical value of cancer-associated myositis-specific antibodies, anti-transcriptional intermediary factor 1- $\beta$ , and anti-nuclear matrix protein 2 antibodies in a retrospective cohort of dermatomyositis/polymyositis in a Japanese community hospital. Clinical Rheumatology, 2022, , 1.	1.0	1
93	Serum levels of anti-transcriptional intermediary factor 1- $\beta$ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis. Seminars in Arthritis and Rheumatism, 2022, 55, 152011.	1.6	4

#	ARTICLE	IF	CITATIONS
94	Myopathien. , 2021, , 189-198.		0
95	Aminoacyl-tRNA Synthetases: On Anti-Synthetase Syndrome and Beyond. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	27
96	Autoantibodies and Cancer Association: the Case of Systemic Sclerosis and Dermatomyositis. <i>Clinical Reviews in Allergy and Immunology</i> , 2022, 63, 330-341.	2.9	8
97	Prediction of Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors With a Panel of Autoantibodies: Protocol of a Multicenter, Prospective, Observational Cohort Study. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	7
98	Is it really myositis? Mimics and pitfalls. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101764.	1.4	5
99	Clinical Heterogeneity of Patients With Antinuclear Matrix Protein 2 Antibodyâ€“Positive Myositis: A Retrospective Cohort Study in China. <i>Journal of Rheumatology</i> , 2022, 49, 922-928.	1.0	5
100	Necrotizing myopathy associated with TET2-mutated myelodysplastic syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , 0, , .	0.2	0
101	Autoantibodies: Pathogenic or epiphenomenon. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, , 101767.	1.4	5
102	Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China. <i>Medicina ClÃnica</i> , 2023, 160, 10-16.	0.3	3
103	Subsets of Idiopathic Inflammatory Myositis Enriched for Contemporaneous Cancer Relative to the General Population. <i>Arthritis and Rheumatology</i> , 2023, 75, 620-629.	2.9	7
104	Profile of specific and associated autoantibodies in patients with idiopathic inflammatory myopathies in a Colombian population. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
105	Cancer and myositis: Who, when, and how to screen. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101771.	1.4	5
106	Emergencies in Idiopathic Inflammatory Myopathies. , 2022, , 283-317.		0
107	Heliotrope Rash, Gottron Papules and Ragged Cuticles in Darker Skin. <i>American Journal of Medicine</i> , 2022, , .	0.6	0
109	Cancer associated autoantibodies in idiopathic inflammatory myopathies: A retrospective cohort from a single center in China. <i>Medicina ClÃnica (English Edition)</i> , 2023, 160, 10-16.	0.1	1
110	A rare case of paraneoplastic myositis associated with neuroendocrine carcinoma of the pancreas. <i>Acta Gastro-EnterolÃgica Belgica</i> , 2022, 85, 640-642.	0.4	2
111	Anti-synthetase Syndrome That Relapsed with Pulmonary Arterial Hypertension and Malignancy. <i>Internal Medicine</i> , 2023, 62, 2747-2751.	0.3	1
112	Skin manifestations and autoimmune disturbances in dermatomyositis. , 2023, , 437-446.		0

#	ARTICLE	IF	CITATIONS
113	Paraneoplastic Neurologic Disorders. <i>Current Neurology and Neuroscience Reports</i> , 2023, 23, 67-82.	2.0	6
114	Classification of Immune-Mediated Myopathies. , 2023, , 21-35.		0
115	Idiopathic Inflammatory Myopathies. , 2023, , 37-72.		0
116	Systemic autoimmune rheumatic diseases as paraneoplastic phenomena: 3 illustrative case reports and narrative review of the literature. <i>Acta Clinica Belgica</i> , 2023, 78, 410-417.	0.5	1
117	An Unusual Performance of Polymyositis. <i>Intensive Care Research</i> , 0, , .	0.2	0
118	Diagnostic Yield of Computed Tomography for Cancer Detection in a Tertiary Referral Population of Idiopathic Inflammatory Myositis Patients. <i>Arthritis Care and Research</i> , 0, , .	1.5	0
119	Anti-Mi-2 antibody-positive lung cancer-associated polymyositis. <i>International Cancer Conference Journal</i> , 2023, 12, 173-176.	0.2	1
120	A case of immune mediated necrotizing myositis. <i>American Journal of the Medical Sciences</i> , 2023, 366, e42-e43.	0.4	0
129	Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress. <i>Nature Reviews Rheumatology</i> , 0, , .	3.5	1
131	Myopathien. , 2024, , 225-235.		0